Inventor · Dietzenbach, DE

Frank Osterroth

14Patents
4h-index
27Co-inventors
52Inventor score

Filing activity: Dec 23, 2008 → Jan 7, 2015

Most-cited inventions

PatentTitleAreaCited byStatus
US9011864B2 Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates Chemistry; Metallurgy 16 Active
US10117932B2 Uses of immunoconjugates targeting CD138 Human Necessities 7 Active
US9289509B2 Uses of immunoconjugates targeting CD138 Performing Operations; Transporting 6 Active
US9221914B2 Agents targeting CD138 and uses thereof Chemistry; Metallurgy 5 Active
US8956607B2 Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE) Chemistry; Metallurgy 4 Active
US9387261B2 Immunoconjugates targeting CD138 and uses thereof Chemistry; Metallurgy 3 Active
US8852871B2 Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) Chemistry; Metallurgy 2 Active
US9334325B2 Method for treating psoriasis Chemistry; Metallurgy 1 Active
US9446146B2 Methods and agents for improving targeting of CD138 expressing tumor cells Chemistry; Metallurgy 1 Active
US9550831B2 Method for treating psoriasis Chemistry; Metallurgy 0 Active
US9605066B2 Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) Chemistry; Metallurgy 0 Active
US9540436B2 Use of antibodies for detection of IL-10 Chemistry; Metallurgy 0 Active
US9995733B2 Agents for treating disease Physics 0 Active
US9512226B2 Agent for treating disease Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.